Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CLR 131
CLR 131
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
CP Wire
Wed, 07/18/18 - 10:54 am
Cellectar
CLR 131
diffuse large B-cell lymphoma
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Wed, 07/18/18 - 09:58 am
Cellectar
CLR 131
diffuse large B-cell lymphoma
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
CP Wire
Thu, 05/10/18 - 11:08 pm
Cellectar
FDA
orphan drug
CLR 131
rhabdomyosarcoma
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
Thu, 05/10/18 - 10:58 pm
Cellectar
CLR 131
rhabdomyosarcoma